Lexaria Bioscience Corp.
NASDAQ
Closed
Jul 17, 2026
Day's Range
0.549052 wk Range
0.4600Key Statistics
Symbol
LEXX
Name
Lexaria Bioscience Corp.
Currency
USD
Exchange
NASDAQ
High
0.64800000
Low
0.54900002
Open
‪0.5600‬
Last
‪0.6360‬
Market Cap
15.76M
Pe Ratio
‪-0.98‬
Volume
131.20K
Average Volume
84.08K
Dividend Yield
‪0.00%‬
Change
0.08
Percent Change
13.77
Timestamp
2026-07-17
Close
0.63599998
Today Range Start
‪0.5490‬
Today Range End
‪0.6480‬
52 Week Range Start
‪0.4600‬
52 Week Range End
‪1.55‬
Type
Stocks
Country
Canada
Compliance - LEXX - Lexaria Bioscience Corp.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-17
Business Screen
COMPLIANT
Financial Screen
NON_COMPLIANT
Compliant Revenue
‪97.00%‬
Non Compliant Revenue
‪2.00%‬
Questionable Revenue
‪1.00%‬
Securities To Market Cap Ratio
‪50.00%‬
Debt To Market Cap Ratio
‪90.00%‬
Historical Data - LEXX - Lexaria Bioscience Corp.
Historical Data
Market Cap - LEXX - Lexaria Bioscience Corp.
Market Cap
2026-07-17
15.76M
2026-07-16
13.86M
2026-07-15
14.57M
2026-07-14
14.55M
2026-07-13
14.74M
2026-07-10
16.02M
2026-07-09
15.24M
2026-07-08
14.99M
2026-07-07
13.14M
2026-07-06
13.86M
Earnings - LEXX - Lexaria Bioscience Corp.
Earnings
Balance Sheet - LEXX - Lexaria Bioscience Corp.
Balance Sheet
| Period Ending | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
|---|---|---|---|---|---|---|
 Assets | 4.17M | 8.86M | 3.08M | 7.83M | 13.26M | 2.82M |
| Liabilities | 1.57M | 1.20M | 403.90K | 201.43K | 203.26K | 345.98K |
| Shareholders Equity | 2.60M | 7.65M | 2.68M | 7.63M | 13.06M | 2.48M |
Cash Flow - LEXX - Lexaria Bioscience Corp.
Cash Flow
| Period Ending | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 1.80M | 6.49M | 1.35M | 5.81M | 10.91M | 1.29M |
| Income Tax Paid | - | 10.04K | 8.21K | 4.78K | 16.29K | 12.97K |
| Interest Paid | - | - | - | - | - | - |
| Free Cash Flow | -10.55M | -5.14M | -6.05M | -5.05M | -4.06M | -2.65M |
Income Statement - LEXX - Lexaria Bioscience Corp.
Income Statement
| Period Ending | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
|---|---|---|---|---|---|---|
| Sales | 705.92K | 464.27K | 226.20K | 255.39K | 722.73K | 384.54K |
| Cost of Goods | 2.72K | 4.82K | 31.50K | 71.84K | 175.34K | 99.37K |
| Gross Profit | 703.20K | 459.45K | 194.70K | 183.55K | 547.39K | 215.41K |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | -11.88M | -5.75M | -6.53M | -6.61M | -5.68M | -4.14M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -33.71K | -69.83K | -221.69K | -764.61K | 1.52M | -96.33K |
| Pre Tax Income | -11.91M | -5.80M | -6.71M | -7.38M | -4.16M | -4.14M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -11.91M | -5.80M | -6.71M | -7.38M | -4.18M | -4.08M |
| EPS Basic | -0.66 | -0.47 | -1.01 | -1.24 | -0.95 | -1.47 |
| EPS Diluted | -0.66 | -0.47 | -1.01 | -1.24 | -0.95 | -1.47 |
| Basic Shares Outstanding | 17.99M | 12.38M | 6.61M | 5.88M | 4.39M | 2.77M |
| Diluted Shares Outstanding | 17.99M | 12.38M | 6.61M | 5.88M | 4.39M | 2.77M |
| Ebit | -11.88M | -5.75M | -6.53M | -6.61M | -5.68M | -4.14M |
| Ebitda | -11.75M | -5.60M | -6.16M | -5.75M | -7.06M | -4M |
| Net Income Continuous Operations | -11.91M | -5.80M | -6.71M | -7.38M | -4.18M | -4.08M |
| Minority Interests | 9.59K | 13.30K | 47.62K | 114.32K | 159.14K | 150.61K |
| Preferred Stock Dividends | - | - | - | - | - | - |
Recommendations - LEXX - Lexaria Bioscience Corp.
Recommendations
Profile - LEXX - Lexaria Bioscience Corp.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
7
Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH. The primary function of this platform is to improve the speed and efficiency of oral absorption of active pharmaceutical ingredients, with potential applications extending across a wide range of industries, including pharmaceuticals, nutraceuticals, consumer packaged goods, and more. Lexaria's technology aims to provide alternative product formulations that offer improved bioavailability and taste masking without altering the stimulant properties of the active compounds. By operating at the intersection of drug development and consumer health, the company plays a pivotal role in advancing innovative delivery solutions, contributing to the growing market of next-generation wellness products. Lexaria Bioscience Corp. continues to partner with organizations intent on developing products that integrate its advanced technology, seeking to capitalize on emerging markets where efficient delivery systems for bioactive substances are increasingly in demand.
Profile Details
Type
Common Stock
Ceo
Mr. Richard C. Christopher
Address
740 McCurdy Road
City
Kelowna
State
BC
Zip
V1X 2P7
Country
Canada
Phone
250 765 6424
